• In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one¹
   
• In a pre-specified secondary endpoint, fewer patients had intra-retinal fluid and/or sub-retinal fluid at week 16 and year one with Beovu¹
   
• In a key pre-specified secondary endpoint, over half of Beovu 6mg patients (56% in HAWK and 51% in HARRIER) were maintained on three-month dosing intervals immediately after the loading phase through year one¹
    …